Logo Skip to main content
  • About
    • Mission
    • Leadership
    • Board of Directors
  • Our Approach
    • Why It Matters
  • Pipeline
    • About TYK2
    • ESK-001
      • Clinical Programs
    • A-005
  • Careers
    • Job Opportunities
    • Values
    • Life at Alumis
  • News
    • Press Releases
      • 062923
      • 092822
      • 090822
      • 080322
      • 040622
      • 010622
      • 092321
      • 081921
      • 072121
      • 050521
    • Media Contact
  • Contact

Press Releases

2023

June 29, 2023
Alumis Announces Expansion of Allosteric TYK2 Inhibitor, ESK-001, Phase 2 Program into Systemic Lupus Erythematosus (SLE) and Uveitis

2022

Sept 28, 2022
Alumis Announces Initiation of Patient Dosing in Phase 2 Clinical Trial of ESK-001 for the Treatment of Plaque Psoriasis

Sept 8, 2022
Alumis Appoints Jörn Drappa M.D., Ph.D., as Chief Medical Officer and Roman G. Rubio, M.D., as Senior Vice President, Clinical Development and Translational Medicine

Aug 3, 2022
Alumis Appoints Sapna Srivastava, Ph.D., to its Board of Directors
 

Apr 6, 2022
Alumis Expands Industry-Leading Leadership Team With Appointments of Sara Klein as General Counsel and Secretary and John R. Schroer as 

Jan 6, 2022
Esker Therapeutics Announces Name Change to Alumis and Completion of $200 Million Series B Financing to Advance Precision Medicines for Autoimmune Diseases

2021

Sept 23, 2021
Esker Therapeutics Announces Management and Research Team Additions to Accelerate Advancement of Precision Immunology Therapies

Aug 19, 2021
Esker Therapeutics Appoints Jeff Douglas as Vice President of Clinical Operations

July 21, 2021
Esker Therapeutics Appoints New Team Members and Board Director

May 5, 2021
Esker Therapeutics Launches to Transform the Treatment of Autoimmune Diseases

  • Home
  • About
    • Mission
    • Leadership
    • Board of Directors
  • Our Approach
    • Why It Matters
  • Pipeline
    • About TYK2
    • ESK-001
      • Clinical Programs
    • A-005
  • Careers
    • Job Opportunities
    • Values
    • Life at Alumis
  • News
    • Press Releases
      • 062923
      • 092822
      • 090822
      • 080322
      • 040622
      • 010622
      • 092321
      • 081921
      • 072121
      • 050521
    • Media Contact
  • Contact
Alumis Inc. Logo

Alumis Inc.
280 East Grand Avenue
South San Francisco
CA 94080
(650) 231-6625

Contact

Business Development
bd@alumis.com

General Inquiries
info@alumis.com

Careers
careers@alumis.com

  • LinkedIn
  • Twitter
  • Privacy Policy
© 2023 Alumis Inc. All rights reserved.
Website Design: Hane Chow, Inc.